Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Dranitsaris G, Lacouture ME (2014) Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. Breast Cancer Res Treat 147(3):631–638PubMedCentralPubMedCrossRef
2.
Jeckel JF, Katz DL, Elmore JG, Wild DMG (2007) The study of causation in epidemiologic investigation and research. In: Jeckel JF (ed) Epidemiology, biostatistics and preventive medicine, 3rd edn. Elsevier, Philadelphia, pp 64–66
3.
Rothman KJ, Greenland S, Lash TL (2008) Cohort studies. In: Rothman KJ (ed) Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Baltimore, pp 79–85
4.
5.
Metadata
Title
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine: rule of thumb in prediction studies
Author
Siamak Sabour
Publication date
01-11-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3173-6

Other articles of this Issue 2/2014

Breast Cancer Research and Treatment 2/2014 Go to the issue

Preclinical study

Effects of Tamoxifen and oestrogen on histology and radiographic density in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers

Clinical trial

Frozen section evaluation of breast carcinoma sentinel lymph nodes: a retrospective review of 1,940 cases

Clinical trial

Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer

Epidemiology

Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research

Brief Report

Upper extremity bioimpedance before and after treadmill testing in women post breast cancer treatment

Epidemiology

Metabolic syndrome and outcomes following early-stage breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits